|
Cytomx Therapeutics, Inc. (CTMX) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
CytomX Therapeutics, Inc. (CTMX) Bundle
¡Descubra el verdadero valor de Cytomx Therapeutics, Inc. (CTMX) con nuestra calculadora DCF avanzada! Ajuste los supuestos clave, explore varios escenarios y evalúe cómo los cambios afectan la valoración de CytomX, todo dentro de una sola plantilla de Excel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.5 | 100.4 | 69.6 | 53.2 | 101.2 | 129.2 | 165.0 | 210.6 | 268.9 | 343.4 |
| Revenue Growth, % | 0 | 74.58 | -30.68 | -23.59 | 90.38 | 27.67 | 27.67 | 27.67 | 27.67 | 27.67 |
| EBITDA | -138.9 | -78.0 | -113.3 | -98.9 | -4.3 | -98.7 | -126.0 | -160.9 | -205.4 | -262.3 |
| EBITDA, % | -241.57 | -77.69 | -162.9 | -186.02 | -4.26 | -76.39 | -76.39 | -76.39 | -76.39 | -76.39 |
| Depreciation | 2.6 | 5.5 | 5.8 | 5.9 | 2.2 | 8.1 | 10.4 | 13.3 | 17.0 | 21.7 |
| Depreciation, % | 4.53 | 5.44 | 8.39 | 11.02 | 2.15 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 |
| EBIT | -141.5 | -83.4 | -119.2 | -104.7 | -6.5 | -100.7 | -128.5 | -164.1 | -209.5 | -267.5 |
| EBIT, % | -246.1 | -83.13 | -171.29 | -197.03 | -6.41 | -77.91 | -77.91 | -77.91 | -77.91 | -77.91 |
| Total Cash | 296.1 | 316.1 | 305.2 | 193.7 | 174.5 | 129.2 | 165.0 | 210.6 | 268.9 | 343.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .8 | .8 | 36.0 | 3.4 | 18.9 | 24.1 | 30.8 | 39.3 | 50.2 |
| Account Receivables, % | 0.02261302 | 0.79512 | 1.14 | 67.69 | 3.39 | 14.61 | 14.61 | 14.61 | 14.61 | 14.61 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0.000001739463 | 0.000000996 | 0.000001437339 | 0 | 0 | 0.000000835 | 0.000000835 | 0.000000835 | 0.000000835 | 0.000000835 |
| Accounts Payable | 4.2 | 3.0 | 2.8 | 2.8 | 1.5 | 5.4 | 6.9 | 8.8 | 11.3 | 14.4 |
| Accounts Payable, % | 7.23 | 2.99 | 4.05 | 5.28 | 1.44 | 4.2 | 4.2 | 4.2 | 4.2 | 4.2 |
| Capital Expenditure | -3.5 | -2.3 | -1.6 | -1.7 | -.8 | -3.8 | -4.9 | -6.2 | -8.0 | -10.2 |
| Capital Expenditure, % | -6.08 | -2.3 | -2.31 | -3.27 | -0.82992 | -2.96 | -2.96 | -2.96 | -2.96 | -2.96 |
| Tax Rate, % | 117.12 | 117.12 | 117.12 | 117.12 | 117.12 | 117.12 | 117.12 | 117.12 | 117.12 | 117.12 |
| EBITAT | -140.9 | -58.6 | -115.0 | -102.6 | 1.1 | -73.3 | -93.6 | -119.6 | -152.6 | -194.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -137.6 | -57.4 | -110.9 | -133.7 | 33.6 | -80.5 | -91.8 | -117.3 | -149.7 | -191.2 |
| WACC, % | 8.7 | 8.51 | 8.68 | 8.69 | 8.04 | 8.52 | 8.52 | 8.52 | 8.52 | 8.52 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -478.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -195 | |||||||||
| Terminal Value | -2,989 | |||||||||
| Present Terminal Value | -1,986 | |||||||||
| Enterprise Value | -2,464 | |||||||||
| Net Debt | -3 | |||||||||
| Equity Value | -2,461 | |||||||||
| Diluted Shares Outstanding, MM | 74 | |||||||||
| Equity Value Per Share | -33.35 |
What You Will Get
- Pre-Filled Financial Model: CytomX Therapeutics’ actual data enables precise DCF valuation.
- Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers specific to (CTMX).
- Instant Calculations: Automatic updates ensure you see results as you make changes to your projections.
- Investor-Ready Template: A refined Excel file designed for professional-grade valuation of (CTMX).
- Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts of (CTMX).
Key Features
- Customizable Clinical Parameters: Adjust essential inputs such as patient enrollment rates, trial durations, and treatment costs.
- Instant Valuation Insights: Generates intrinsic value, net present value (NPV), and additional metrics on demand.
- High-Precision Forecasting: Utilizes CytomX’s actual clinical data for accurate valuation projections.
- Simplified Scenario Testing: Easily evaluate various hypotheses and analyze results side by side.
- Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered CytomX Therapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for CytomX Therapeutics' intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose CytomX Therapeutics, Inc. (CTMX) Calculator?
- All-in-One Solution: Combines DCF, WACC, and financial ratio evaluations tailored for CytomX Therapeutics.
- Flexible Inputs: Modify the highlighted fields to explore different financial scenarios.
- In-Depth Analysis: Automatically computes CytomX’s intrinsic value and Net Present Value.
- Integrated Data: Historical and projected figures provide a solid foundation for analysis.
- Expert-Level Tool: Perfect for financial analysts, investors, and industry consultants focused on biotechnology.
Who Should Use CytomX Therapeutics, Inc. (CTMX)?
- Investors: Gain insights into innovative cancer therapies with a focus on targeted treatments.
- Healthcare Analysts: Utilize comprehensive data to evaluate the potential of pipeline products.
- Consultants: Tailor research findings for client briefings or strategic planning sessions.
- Biotech Enthusiasts: Expand your knowledge of therapeutic development through case studies and real-world applications.
- Educators and Students: Leverage it as a resource for learning about biotech advancements in academic settings.
What the Template Contains
- Preloaded CTMX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.